INCREASED CLINICAL AND ECONOMIC BENEFIT IN SPAIN ASSOCIATED WITH IMPROVEMENT TO ±8.5% OF THE ACCURACY OF GLUCOSE METERS ADAPTED TO THE CURRENT ISO 15197-2013 (±15%)
Author(s)
Sanz-Granda Á1, Artola-Menéndez S2, Franch-Nadal J3, Mata-Cases M3, Merino-Torres JF4
1Proyectos de Farmacoeconomía, Navacerrada (Madrid), Spain, 2CS José Marvá, Madrid, Spain, 3Fundación redGPDS, DAP_CAT, Barcelona, Spain, 4Hospital Universitari i Politècnic La Fe, Valencia, Spain
OBJECTIVES: The current ISO 15197:2013 has improved the accuracy of glucose meters, ±15%, (GM-2013), by reducing the frequency of false negative readings; this allows a better control of the treatment. It has been shown that this reduces the incidence of macro/microvascular events and hypoglycemic episodes. The aim was to estimate the improvement of clinical and economic outcomes in Spain associated with glucose meters of higher accuracy, ±8.5%, (GM-2016), compared to ±15% GM-2013. METHODS: All diabetes Spanish patients, type 1 (DM1) and 2 (DM2), were included. The incidence of false negative readings was estimated from current GM-2013 and new GM-2016; after that, the frequency of potential and associated hypoglycemic and hypoglycemic events was calculated. Finally, the management cost of those events was estimated for GM-2013 and GM-2016. Clinical and economic benefit was calculated as the difference in the results (number of events and the total costs) in both scenarios. RESULTS: Total cost of test strips used in the self-monitoring blood glycaemia was €480,138,728 (in 116,058 DM1 and 956,482 DM2 patients). 2,055 and 1,223 hyperglycemic events, and 16,448 and 7,698 hypoglycemic episodes were estimated with GM-2013 and GM-2016, respectively. Total cost for managing those was €140,865,956 and €133,122,487, respectively. It resulted in a net saving of €7,743,469 yearly, associated to the use of GM-2016 (±8.5% accuracy) instead GM-2013, adapted to current ISO 15197:2013 (±15% accuracy). CONCLUSIONS: The use of glucose meters having higher accuracy (±8.5%) than required by current ISO 15197:2013 (±15%), would increase clinical benefit by reducing the incidence of complications and would be associated with cost savings (7.74 mill€), equivalent to 6.2% of test strip total cost
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PMD28
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Diabetes/Endocrine/Metabolic Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now